ReviewInternational journal of molecular sciences2020
Hematopoietic Stem Cell Transplantation in Neuromyelitis Optica-Spectrum Disorders (NMO-SD): State-of-the-Art and Future Perspectives.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Exploration of the causal associations between circulating inflammatory proteins, immune cells, and neuromyelitis optica spectrum disorder: a bidirectional Mendelian randomization study and mediation analysis.Frontiers in aging neuroscience · 2024Article
- Hematopoietic stem cell transplantation as rescue therapy for refractory autoimmune retinopathy: a case report.Frontiers in immunology · 2024Article
- A Clinical Approach to Existing and Emerging Therapeutics in Neuromyelitis Optica Spectrum Disorder.Current neurology and neuroscience reports · 2023Review
- Hematopoietic Stem Cell Transplantation for the Treatment of Autoimmune Neurological Diseases: An Update.Bioengineering (Basel, Switzerland) · 2023Review
- Research hotspots and trends on neuromyelitis optica spectrum disorders: insights from bibliometric analysis.Frontiers in immunology · 2023Review
- Derivation and characteristics of induced pluripotent stem cells from a patient with acute myelitis.Frontiers in cell and developmental biology · 2023Article
- Treatment and Relapse Prevention of Typical and Atypical Optic Neuritis.International journal of molecular sciences · 2022Review
- Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): Novel insights into therapeutic possibilities in NMOSD.CNS neuroscience & therapeutics · 2022Review
- Hypoxia drives hematopoiesis with the enhancement of T lineage through eliciting arterial specification of hematopoietic endothelial progenitors from hESC.Stem cell research & therapy · 2022Article
- Pediatric Neuromyelitis Optica Spectrum Disorder: Case Series and Literature Review.Life (Basel, Switzerland) · 2021Review
- Cells to the Rescue: Emerging Cell-Based Treatment Approaches for NMOSD and MOGAD.International journal of molecular sciences · 2021Review
- Neuromyelitis Optica Spectrum Disorder Treatment-Current and Future Prospects.International journal of molecular sciences · 2021Review
- B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Drug Treatment of Neuromyelitis Optica Spectrum Disorders: Out with the Old, in with the New?ImmunoTargets and therapy · 2021Review
- The role and mechanisms of Microglia in Neuromyelitis Optica Spectrum Disorders.International journal of medical sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorders (NMOSD) are a group of autoimmune inflammatory disorders of the central nervous system (CNS). Understanding of the molecular basis of these diseases in the last decades has led to an important improvement in the treatment of this disease, in particular, to the use of immunotherapeutic approaches, such as monoclonal antibodies and Hematopoietic Stem Cell Transplantation (HSCT). The aim of this review is to summarize the pathogenesis, biological basis and new treatment options of these disorders, with a particular focus on HSCT applications. Different HSCT strategies are being explored in NMOSD, both autologous and allogeneic HSCT, with the new emergence of therapeutic effects such as an induction of tolerance to auto-antigens and graft versus autoimmunity effects that can be exploited to hopefully treat a disease that still has prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.